Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms

Randomised, double-blind, parallel-group study comparing psilocybin dosing days with daily escitalopram or placebo over a 6-week comparator period in adults with moderate-to-severe major depressive disorder.

Outcomes include clinical depression measures and mechanistic investigations (neuroimaging and related biomarkers); eligibility required HAM-D ≥17 and excluded current or familial psychotic disorders and significant medical contraindications.